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1. Introduction
Inherited forms of thrombophilia such as factor V Leiden mutation (FVL), prothrombin gene
mutation (PT 20210A), and deficiencies of natural anticoagulants protein C, protein S, and
antithrombin are well known. DNA tests for factor V Leiden and PT 20210A mutation have
been incorporated in clinical practice for several years [1,2,3]. A number of studies have
analyzed how this and other molecular genetic testing alter the clinical management and
treatment of patients with thromboembolic disease or pregnancy complications. Data regard‐
ing the influence of the genotype to the disease phenotype as well as pharmacogenetic data
are still controversial and emerging.
Several topics are of particular interest. Usually genetic tests follow standard investigation of
coagulation cascade, but some laboratories perform them in initially. Testing of first-degree
relatives of a diagnosed carrier of a thrombophilic trait is still not consecutive. Administration
of anticoagulant therapy is followed by genetic tests also; DNA variations are associated with
variations in drug efficacy and toxicity, particularly in cases of warfarin and clopidogrel.
Investigation of inherited thrombophilia and its treatment in women with reproductive
challenges, including in vitro fertilization (IVF), is another important question. Finally,
recommendation for genetic testing and treatment of thrombophilia in children, as vulnerable
group, should be clarified.
2. Thromophilia screening and treatment in asymptomatic adult carriers
Thrombophilia testing is one of the most common genetic tests ordered by clinicians [4].
Current guidelines recommend screening for inherited thrombophilia only in selected group
of patients with venous thromboembolism, dependently of the age of onset, the circumstances
of thrombosis, and the severity of the clinical manifestations [5,6].
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When the results of the index patients are positive asymptomatic relatives often come with
requests for thrombophilia testing. To date, there is variety of published guidelines. However,
the utility of family testing remains matter of debate and it should be done with caution. It is
a general knowledge that genetic testing is justified only if the results are likely to change
medical management. American College of Medical Genetics (ACMG) and Evaluation of
Genomic Applications in Practice and Prevention (EGAPP) working group published consen‐
sus statements on FVL and FII. According to ACMG it is not recommended to perform random
screening of general population or prenatal and routine newborn screening [7]. Based on the
current knowledge, identification of thrombophilic disorders in asymptomatic individuals
would not lead to long-term treatment with anticoagulants since the risk of bleeding is higher
than the risk of venous thromboembolism (VTE) [7]. The overall annual incidence of the first
VTE in individuals with antithrombin, protein C or protein S deficiency is ~1.5 %, whereas for
the factor V Leiden or prothrombin 20210A mutation heterozygote this risk is ~0.5% [8]. Annual
major bleeding risk associated with continuous anticoagulant treatment is around 2% and it
overweighs the risk of VTE [9]. The results of Middeldorp et al. on asymptomatic carriers of
FVL, are in agreement with the above and since there is no clear evidence of the benefit of
thrombophylaxis they do not recommend routine screening of families of symptomatic
patients [10]. Also, Coppens et al. do not recommend testing first degree relatives of probands
with the prothrombin 20210A mutation based on the results of a large prospective cohort study
in which the annual incidence of a first VTE in PT carriers was 0.37% [11]. For asymptomatic
family members who are homozygous for FVL mutation the risk increases to closely 2%.
According to EGAPP the risk is sufficient to consider anticoagulation therapy but there are
still no data about the outcomes [12].
The practice of family testing has been most useful for women from thrombophilic families
who intend to be pregnant. Affected female relatives with antithrombin, protein C and protein
S deficiency as well as FVL and 20210A mutation carriers have VTE incidence as high as 4%
per pregnancy while women homozygous for FVL have the risk of 16% per pregnancy in the
absence of prophylaxis [13]. In these cases anticoagulant therapy, usually low molecular
heparin injections, is frequently applied.
Genetic testing is also very useful for women from thrombophilic families who wish to use
oral contraceptives. Use of oral contraceptives increases the risk of VTE for women with
antithrombin, protein C or protein S protein deficiency or FVL and 20210A mutation. However,
it is important to know that women from thrombophilic families are at the increased risk
(compared with the general population) even if they do not have these specific deficiencies or
mutations, due to the other cosegregating thrombophilic defects [8]. Thus, a negative throm‐
bophilia test may give them false reassurance.
Family testing may also help reduce VTE risk for women who tested positive through
avoidance of postmenopausal hormone therapy. Advantages of testing are even higher for
women considering postmenopausal hormone therapy than oral contraceptives, due to the
much higher absolute risk of VTE in middle-aged than in younger women [13].
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3. Antithrombotic therapy and the promise of pharmacogenetics
The expansion of pharmacogenetics, the study of genetic variants relevant to variations in drug
efficacy and toxicity, and pharmacogenomics, referred to as a whole-genome application of
pharmacogenetics, allowed rapid progress towards the goal of personalized therapy, tailored
for individual patients [14-17].
The research in this field provides large amounts of individual-specific information concerning
risk for adverse reactions or lack of drug efficacy, thus it could have significant influence on
clinical practice. The question of how to use the pharmacogenetic information to improve
health outcomes gains continuously increasing attention [18-20]. Specifically, it has been
shown that pharmacogenetic information has the potential to improve the efficacy and safety
of major antithrombotic drugs (e.g. [21]).
3.1. Warfarin: A case in point
One of the most compelling examples of potential benefits from pharmacogenomic testing is
warfarin [22]. Warfarin is a widely prescribed oral anticoagulant; for decades it has been used
as standard drug to prevent and treat thrombotic events in patients with deep vein thrombosis,
various hypercoagulable states, atrial fibrillation, surgical cardiac valve replacement, etc.
One of the major problems with its use in clinical practice is large interindividual variation –
patients differ in sensitivity to warfarin, hence the dose requirements vary widely (up to 20-
fold) [19,23]. The consequences of over- or under-anticoagulation can be serious. In patients
less sensitive than typical, the standard doses may be too low to achieve anticoagulation and
therapeutic failure may occur, while in highly sensitive individuals the same doses may lead
to serious adverse effects, such as hemorrhage.
Numerous factors are known to impact dose variation, including age, dietary vitamin K intake,
presence of other comorbidities and interactions with other drugs, as well as genetic variants.
The identification of these variants, and the potential use of pharmacogenetic testing to predict
the appropriate drug dosing have attracted much research interest [23-28].
Prior work pointed to significant genetic component underlying variations in warfarin
sensitivity. Pharmacogenetic studies identified polymorphisms in genes CYP2C9 and VKORC1
as principal genetic determinants of warfarin dose [23,24,29].
CYP2C9 gene encodes one of the major cytochrome P450 drug-metabolizing enzymes; it is
involved in metabolic clearance of S-warfarin, the more potent isomer of warfarin, which is
largely responsible for its therapeutic effects. Two common alleles are described, CYP2C9*2
and CYP2C9*3, based on non-synonymous SNPs that result in Arg144Cys (*2) and Ile358Leu
(*3) substitutions; both variants are associated with reduced metabolic clearance of S-warfarin,
thus lowering dose requirements [24]. Carriers of these variants show high sensitivity to drug
and increased risk for hemorrhagic complications compared to individuals homozygous for
allele *1. It is estimated that SNPs in CYP2C9 gene account for approximately 12% of the total
variance in required warfarin dose [23] (range 6–18%, [18]).
Pharmacogenetics and the Treatment of Thrombophilia
http://dx.doi.org/10.5772/56566
Larger proportion of the dose variance, up to 30%, is explained by SNPs in the gene VKORC1
[25,29]. VKORC1 encodes vitamin K epoxide reductase complex, the target enzyme inhibited
by warfarin; this enzyme is necessary for the recycling of vitamin K and consequently for
activation of several clotting factors. Currently, several VKORC1 SNPs are described (the major
one being VKORC1 -1639G>A, a common polymorphism of the promoter sequence) that define
two common haplotypes, A and B. Haplotype A is associated with higher warfarin sensitivity,
and hence lower mean drug doses required, contrary to B haplotype [29].
With respect to frequencies of these variants, genetic differences between populations are also
a matter of great interest. The common CYP2C9 alleles *2 and *3, associated with high warfarin
sensitivity, are present in approximately 30% of people of European descent (range 13-35%),
but are less frequent in those of Asian (1-12%) and African descent (0-12%) [21,25,30]. VKORC1
B haplotype, associated with low warfarin sensitivity, is more common in European and
African populations, while ‘high sensitivity’ A haplotype predominates in Asian populations.
The frequency of A is reported as 75–92% in Asians, compared to approximately 40% in
Europeans or 9–12% in people of African descent [21].
To predict response to treatment, considering polymorphisms in both genes simultaneous‐
ly is of great importance. Carriers of variants associated with ‘high sensitivity’ at both loci
are at much higher risk of over-anticoagulation [31]. On the other hand, individuals who
are CYP2C9*1*1-VKORC1BB show less warfarin sensitivity and require higher drug dose
for therapeutic anticoagulation [25]. The associated variants in both genes are thought to
account  for  approximately  45%  of  response  variance  in  European  and  30%  in  African
populations [21].
The frequency of VKORC1 and CYP2C9 alleles was also investigated in Serbian population,
among patients under oral anticoagulant therapy [32,33]. In a group of patients with extremely
unstable anticoagulant response, 89.7% were carriers of ‘sensitivity’ alleles, and 25% carried
these variants at both CYP2C9 and VKORC1 loci [33].
A recent genome wide association study (GWAS) by Takeuchi et al. confirmed polymorphisms
in genes VKORC1 and CYP2C9 as principal genetic determinants of warfarin dose and also
found weaker, but still significant effect of polymorphism in another CYP gene, CYP4F2 [23].
The effect of CYP4F2 rs2108622 was confirmed by other authors (e.g. [26,34]).
The results concerning possible contribution of other candidate genes are still inconsistent. The
investigation of other SNPs and CNVs (copy number variations) did not reveal new significant
warfarin associations [23], however, limited positive data was obtained for polymorphisms in
additional candidate genes such as POR (encoding cytochrome P450 oxidoreductase) or CALU
(encoding calumenin) (review in [27]).
The additional polymorphisms in these or other genes relevant to blood coagulation may be
worth further investigation, especially in non-European populations that were less studied
pharmacogenetically [27,28].
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4. Clinical application of pharmacogenetic testing — Promises and
problems
What are the promises and problems of the genotype-guided antithrombotic therapy?
Pharmacogenetic testing has the potential to improve the efficacy and safety of warfarin and
other antithrombotic drugs [21].
Recognizing the significance of the genetic information, US FDA added it to warfarin label in
2007 and suggested that clinicians considered genetic testing before initiating therapy. Genetic
tests for CYP2C9 and VKORC1 ‘sensitivity’ variants are available for clinical use, and so are
dosing algorithms that combine genetic and clinical data [35,36]. Including CYP4F2 rs2108622
in testing procedures and algorithms is also suggested [27].
However, the question of routine adoption of pharmacogenetic testing for warfarin sensitivity
into clinical practice has led to vigorous debates. Numerous problems and challenges arise,
from cost-effectiveness analyses, possibility of development of alternative drugs [27], com‐
plexity, quality and time demands, the need for additional education and training, to ethical
and regulatory issues [19,21,36].
The major issue for clinical application of pharmacogenetic testing is that this approach must
provide significant benefit to patients compared to nongenetic approach only. Cost-effective‐
ness emerges as another important question in modern health care; currently, discussions are
focused on the cost of genetic testing vs. potential savings by reducing severe health compli‐
cations [18,19,31,37]. Also, the aim is to identify specific groups of patients who will benefit
most from the pharmacogenetic testing [20], and to obtain diversity of warfarin dosing
algorithms that should reflect genetic diversity of populations [28].
A multicenter study, published in 2009 by the International Warfarin Pharmacogenetics
Consortium, demonstrated that algorithms for warfarin dosing that incorporate pharmaco‐
genomic information were better than those using clinical data alone [35]. The greatest benefits
were observed in patients with extreme (very low or very high) dose requirements. A recent
Medco-Mayo Warfarin Effectiveness study demonstrated that application of warfarin geno‐
typing significantly reduced the incidence of hospitalizations due to bleeding and throm‐
boembolism [37]. Eckman and colleagues analyzed cost-effectiveness of using
pharmacogenetic approach for patients with atrial fibrillation and concluded that genotype-
guided warfarin therapy might be cost effective in a high-risk group [31].
However, general consensus regarding these questions is lacking. The results of the ongoing
studies and trials, conducted on large scales and diverse populations, are expected to clarify
these issues [21].
With the current pace of pharmacogenetic discoveries, integrating the growing amount of
individual-specific data into clinical practice to improve health outcome will remain the
challenging task.
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5. Genetics and treatment of reproductive adversity in thrombophilia
Clinical manifestations and morbidity associated with thrombophilia in pregnancy include
pregnancy loss, as well as other adverse outcomes eg. preeclampsia, placental abruption, and
intrauterine growth restriction. Pregnancy-related thromboembolism is also part of thrombo‐
philia spectrum making the influence of thrombophilia in pregnancy is an important and
interesting research topic.
The effect of preventive anticoagulant therapy during the pregnancy in women with inherited
thrombophila is still controversial. Early investigations were characterized by small partici‐
pant numbers, poor study design and heterogeneity. The debate on the efficacy of aspirin and
heparin has advanced with recently published randomised-controlled trials. One large Italian
study encompassed 1011 pregnancies of 416 women who were carriers of factor V Leiden (FVL)
mutation and/or prothrombin gene variant G20210A (PTG) [38]. The outcome was evaluated
according to the type of treatment (low molecular weight heparin and/or aspirin) and the
period of pregnancy when the treatment started. The results showed that low molecular weight
heparin (LMWH) had a protective effect on miscarriages (odds ratio, OR 0.52) and venous
thromboembolism (OR 0.05) while aspirin administration showed no advantage on the
prevention of obstetric complications and venous thromboembolism (OR 2.2 and 0.48,
respectively). These results suggest that LMWH prophylaxis reduces the risk of obstetric
complications in carriers of FVL and/or PTG, particularly in those with previous obstetric
events. Mitic et al. also reported significant improvement of pregnancy outcome after imple‐
mentation of thromboprophylaxis in Serbian patients with inherited thrombophilia and
previous pregnancy losses [39].
One Bulgarian group reported their first experience with management of inherited thrombo‐
philia during pregnancy [40]. After the testing for factor V Leiden, prothrombin G20210A,
plasminogen activator inhibitor-1 (PAI-1) 4G/4G and PAI-1 4G/5G they established a diagnosis
of inherited thrombophilia in 72% (24 out of 38) patients with history of an abnormal pregnancy
(miscarriage, still birth, placental abruption, preeclampsia and intrauterine fetal growth
restriction). All diagnosed patients were treated with aspirin (75mg) prior to conception and
low molecular heparin after detection of fetal heart sounds. Anticoagulant treatment of these
patients was deemed successful with 87.5% (21 out of 24) giving birth to a term newborn.
However, several investigators have reported confounding experiences [41-43]. In a recently
published review, de Jong et al suggest that the association between inherited thrombophilia
and recurrent miscarriage is not very strong, and the evidence does not indicate that the use
of anticoagulants improves the chance of live birth in these women [41]. The authors conclude
that by the current state of evidence, testing for inherited thrombophilia should not lead to
altered clinical management and so, should not be performed routinely in women with
recurrent miscarriage. In light of the available data, a well-designed, multi-center collaboration
is required to ascertain the effect of inherited thrombophilia on early pregnancy loss and to
establish evidence-based treatment recommendations [44].
It may be possible that in women with recurrent pregnancy loss multiple thrombophilic gene
mutations rather than specific single gene changes play a role. In one study, 10 gene mutations
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were analyzed: factor V Leiden, factor V H1299R (R2), factor V Y1702C, prothrombin gene
G20210A, factor XIII V34L, beta-fibrinogen -455G>A, PAI-1 4G/5G, human platelet alloantigen
a/b (L33P), methylenetetrahydrofolate reductase C677T and A1298C [45]. There were no
differences in the frequency of specific mutations in women with recurrent miscarriage
compared to healthy control. However, the prevalence of homozygous mutations and total
gene mutations was significantly higher in patients compared to controls. Homozygous
mutations were found in 59% of women with a history of recurrent pregnancy loss vs. 10% of
control women. More than three gene mutations were observed in 68% of women with
recurrent miscarriage compared to 21% of controls. It would be of especial interest to explore
how number of detected mutations influences effects of prophylactic therapy and further
reproductive outcome.
The possible connection between inherited thrombophilia and outcomes of in vitro fertili‐
zation (IVF) is another challenging topic. A number of investigations suggest no associa‐
tion of thrombophilic mutations and IVF pregnancy failure [46,47]. Rudick et al. found a
very low prevalence of  FVL mutation in women in their  IVF program (1.6%),  and sug‐
gested  a  positive  association  between  this  genetic  marker  and  pregnancy  [47].  The  au‐
thors  suggested that  routine testing in a  general  IVF population for  FVL mutation as  a
cause of IVF failure and infertility is not indicated. Ricci et al. compared the prevalence of
FVL and PTG mutation in women undergoing IVF to women with spontaneous pregnan‐
cy,  as  well  as  IVF outcomes  and the  risk  of  complications  in  FVL and PTG carriers  to
non-carriers  [48].  In  this  prospective  cohort  study  they  found  the  same  prevalence  of
thrombophilic mutations in women requiring IVF and in women with spontaneous preg‐
nancy. The results of this study also suggested the presence of FVL and PTG in asympto‐
matic  women  and  in  the  absence  of  other  risk  factors  did  not  influence  IVF  outcome,
represent  a  risk  for  ovarian  hyperstimulation  syndrome,  or  favor  thrombosis  after  IVF.
According to these authors, screening for FVL and PTG does not appear to be justified to
identify the patients at the risk for IVF failure or associated complications.
However, some studies have shown positive effects of LMWH treatment for women with
thrombophilia and recurrent IVF- embrio transfer failures [49,50]. In one prospective random‐
ized placebo-controlled trial Qublan et al. observed that implantation rate, pregnancy and live
birth rates are significantly increased with LMWH compared to placebo [49]. At this moment,
diagnostic tools to identify patients at risk of implantation failure are still limited and thera‐
peutic options to improve implantation rates are far from being established. In addition to
genetic markers of thrombophilia and thromboprophylaxis, different immunological mecha‐
nisms and consecutive immunomodulatory treatments are the subjects of intensive investiga‐
tions [51].
6. Thrombophilia screening in asymptomatic children
Parents with known specific thrombophilic defect frequently ask whether or not their
child(ren) should also be screened for thrombophilia. Many of them are concerned about their
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children’s health, mostly the risk of having VTE or reproductive issues, especially if the mother
was diagnosed during pregnancy or after several pregnancy losses. Genetic testing is partic‐
ularly controversial in children since their decision-making capability is non-existent or is
limited [52].
The recommendation of  The American Academy of  Pediatrics  (AAP) and the ACMG is
that  predictive  genetic  testing  for  late-onset  disorders  should  not  be  performed  unless
there is a specific intervention during childhood that will  reduce morbidity or mortality
[53,54].  Also,  the AAP does not support the broad use of carrier testing or screening in
children or adolescents.  As for  any genetic  testing,  a  medical  benefit  should be the pri‐
mary justification for testing in children and adolescents. It is very important for parents
to understand the limitations of testing before they sign informed consent for their chil‐
dren. The results of thrombophilia testing rarely influence medical management decisions
and at the moment there is no evidence that thrombophilia testing could benefit a young
healthy child.  The incidence of  venous thrombosis  in  healthy children is  extremely low
(0.07/100000),  and the long-term use of anticoagulants in an asymptomatic healthy child
would be unjustified [55].
Tormene et al. performed a prospective cohort study of children aged 1-14 years from families
with a single identified inherited thrombophilia. The children were tested for FVL, prothrom‐
bin G20210A mutations and antithrombin, protein C and protein S deficiency and followed
for the evidence of thrombosis 1-8 years (mean 5 years). No children with or without throm‐
bophilia developed VTE during the study period [56]. Thrombophilia testing could show more
benefit for children with the acute or chronic medical conditions. The overwhelming majority
of pediatric TEs are associated with central venous lines (CVLs) [52].
Other acquired risk factors depend on the age of the child.  Within the entire childhood
population neonates are at  the greatest risk of thromboembolism (5.1/100 000 live births
per year in white children) [57]. Neonatal risk factors include birth asphyxia, respiratory
distress  syndrome,  maternal  diabetes,  infections,  necrotizing  enterocolitis,  dehydration,
congenital nephrotic syndrome and polycythemia [57]. Children of any age may have an‐
tiphospholipid or anticardiolipin antibodies which are associated with thrombophilia [52].
Meta-analysis  of  Young  et  al.  on  impact  of  inherited  thrombophilia  on  venous  throm‐
boembolism in children showed significant association with recurrent VTE for all inherit‐
ed  thrombophilia  traits  except  the  factor  V  variant  and elevated  lipoprotein  (a)  [58].  A
second peak of incidence of thrombosis is during adolescence [59]. Adolescents may have
the same risk factors as the adults including smoking, pregnancy, obesity, and oral con‐
traceptives which increase the risk of thrombosis [52]. Adolescents identified with an in‐
herited  thrombophilia  may  benefit  from  avoiding  high-risk  situations  (prolonged
immobility,  dehydration),  pursuing  healthy  lifestyles  (regular  exercise  and  weight  con‐
trol), and recognizing early signs and symptoms of VTE [60].
There are some situations in which the presence of an inherited defect may influence medical
decision making. The first is in an adolescent female who is interested in using oral contra‐
ceptive pills (OCPs). Knowledge of a congenital thrombophilia provide the opportunity to
consider lower-risk alternatives for contraception, such as progesterone-only preparations. In
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limited cases, the presence of inherited thrombophilia might lead to targeted thrombophylaxis
in high risk situations, e.g., after a femur fracture in an obese teenager, though there are few
data to document the efficacy of this approach [60].
7. Genetic counseling
It is of major importance to provide genetic counseling to patients as well as to their asymp‐
tomatic family members who are interested in thrombophilia testing, including pharmacoge‐
netic tests. Based on detailed information about a family history, personal history and the
reasons for testing genetic counselor should provide education and support for the family
members. During the pre-test genetic counseling patient or family member should understand
that the testing is optional and that it will be performed only after signed informed consent. It
must be clarified that this is a testing for susceptibility gene and not for the disease state and
that an individual’s thrombotic risk is determined by a complex interplay of genetic, acquired
and circumstantial risk factors [1]. It must be clear to the family member that if thrombophilia
mutation is inherited the risk of VTE is higher than it is in the general population but although
the inheritance pattern is dominant the penetrance of the mutation is not 100%. In order to
achieve a better understanding of potential risk when counseling a family member regarding
the risk of thrombosis it is most useful to provide the absolute risk (e.g., incidence) of throm‐
bosis among persons with particular thrombophilia [61]. Pre-test genetic counseling should
include discussion not only about the risks but also about the benefits and limitations of testing
for the patient and for the entire family. Asymptomatic family member should understand
that testing for thrombophilia may have lower benefit to risk ratio as compared to symptomatic
relative [62]. Post-test counseling is equally as important for family members who tested
positive and negative. In case when the result is negative family members should understand
that currently available tests might not identify all inherited risk factors for thrombosis [52].
In the other case discussion should include signs and symptoms of thrombosis, risk factors to
avoid and the risks and benefits of prophylactic therapy [63]. Clinical geneticist should also
be aware of psychological response of the tested individual. Results of the study of Louzada
et al. do not support the concern that asymptomatic relatives are at risk of psychological
distress as a consequence of thrombophilia screening [64]. However it is general conclusion
that characteristics of the genetic predisposition, including the likelihood of developing the
disease, perceived severity and availability of treatments for the condition are likely contrib‐
utors to the psychological response [64]. It means that adequate genetic counseling is of key
importance for education of family members, in order to increase their awareness of risk factors
and effective interventions to prevent VTE.
As a conclusion, genetic tests are part of modern management and treatment of thrombophilia,
but several medical and ethical dilemmas are still open. Healthcare professionals should apply
evidence-based guidelines regarding indications for genetic and pharmacogenetic testing, as
well as principles of genetic counseling in thrombophilia. In the upcoming era of personalized
genomic medicine, genetic tests day after day become more available, but their real power and
relevance is fully expressed in the context of clinical data.
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